Ozoralizumab – anti-TNFα Nanobody to treat auto-immune disorders
- Ozoralizumab is being developed for the treatment of auto-immune disorders with initial focus on rheumatoid arthritis (RA)
- Ozoralizumab achieved clinical proof-of-concept in a Phase IIa RA study
- Exclusive license agreement signed with Eddingpharm in 2014 to develop and commercialise ozoralizumab in Mainland China, Hong Kong, Macao and Taiwan
- Exclusive license agreement signed with Taisho Pharmaceutical 2015 to develop and commercialise ozoralizumab in Japan
Rheumatoid arthritis (RA)
RA is characterised by chronic and progressive joint inflammation that typically results in permanent, debilitating tissue damage, which is further compounded by joint deformation. The condition is associated with lower quality of life, premature death, disability, and unemployment. It is estimated that up to 1 percent of the adult population worldwide suffer from RA.
Ozoralizumab mode of action
Ozoralizumab (38kD) is a trivalent Nanobody that potently neutralises TNFα and binds to serum albumin to increase its in vivo half-life. TNFα promotes the inflammatory response which in turn causes many of the clinical problems associated with auto-immune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis.
Ablynx is currently looking for partners to develop and commercialise ALX-0141 outside of Greater China and Japan. For further information, please contact Gosia Ciesiolka, Director Business Development.
Related presentations, abstracts and posters
Poster presentation: A novel individualised treatment approach in open-label extension study of ozoralizumab (ATN-103) in subjects with rheumatoid arthritis on a background of methotrexate
Presentation: A Multiple Ascending Dose / Proof of Concept Study of ATN-103 (ozoralizumab) in Rheumatoid Arthritis Subjects on a Background of Methotrexate